Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dmed Biopharmaceutical Co. Ltd.
Headquarters: Shanghai, China
Website: N/A
Year Founded: 2016
Status: Merged
BioCentury | Apr 28, 2021
Deals
dMed goes global through Clinipace merger ahead of planned Hong Kong listing
Tan, Baeder outline path ahead for dMed
BioCentury | Feb 13, 2021
Finance
Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange
Portfolio company New Horizon readies to become first diagnostics play on the Hong Kong exchange’s biotech chapter
BioCentury | Dec 18, 2020
Deals
Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO
Ultragenyx gains ex-Europe rights to Mereo’s setrusumabUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) licensed ex-European rights to setrusumab from Mereo BioPharma Group plc (LSE:MPH;
BioCentury | Jun 20, 2020
Product Development
中国为具有前瞻性思维的生物科技公司提供了不仅仅是临床试验重回正轨的机遇
嘉宾评论： 利用中国的临床基础设施，有助于恢复试验，建立长期优势
BioCentury | Jun 20, 2020
Product Development
China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track
Guest commentary: Tapping China’s clinical infrastructure can help resume trials and build long-term advantage
BioCentury | Feb 8, 2020
Product Development
As coronavirus disrupts MNC operations in China, companies look to digital solutions
Biopharma will need to turn to digital solutions in China in the face of the coronavirus crisis
BioCentury | Nov 18, 2019
Finance
How Quan intends to build cross-border start-ups with second fund
Quan plans to use its $250M second fund to take larger stakes in companies across China, the U.S. and Europe
BioCentury | Nov 18, 2019
Finance
How Quan intends to build cross-border start-ups with its second fund
Quan plans to use its $250M second fund to take larger stakes in companies across China, the U.S. and Europe
BioCentury | Oct 17, 2019
Financial News
Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna
BioCentury | Sep 26, 2019
Tools & Techniques
Biotechs propose solutions to impending shortage of AI talent
With demand for AI talent on the rise, biotechs propose strategies for competing with other sectors
Items per page:
1 - 10 of 16